The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio ...
The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...
Federal agencies must stop disbursing financial assistance under a new budget directive, threatening funding for providers ...
ITM's lutetium-containing therapy extended progression-free survival versus everolimus in patients with a specific kind of ...
The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...
The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.
Helicore, which is developing a GIP-blocking antibody, is the fourth obesity drug developer to receive funding from Versant ...
Pharmacies play a key role in improving drug development and patient care, offering insights, clinical trial support and ...
Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...
In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...
Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback